Nasdaq
$2.37▲ 1.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $133.2MShares out 56.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 8.13Regular26.08.14 01:47SCHEDULE 13G/AOwnership#●●●#●●●
Protara Therapeutics, Inc.
Janus Henderson Group Ltd. has filed a Power of Attorney appointing Kristin Mariani and Caroline Barotti as attorneys-in-fact for ownership reporting of Protara Therapeutics, Inc. This filing establishes the legal authority for 13 affiliated asset managers under Janus Henderson to collectively fulfill their regulatory reporting requirements.…more
$2.37+1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.11After-hours26.08.12 05:15S-8Offering
Protara Therapeutics, Inc.
프로타라 테라퓨틱스(Protara Therapeutics)는 2024년 주식 보상 계획(2024 EIP)에 따라 보통주 5,750,000주를 추가로 등록했습니다. 이번 조치는 2026년 4월 8일 이사회 결의 및 6월 12일 주주총회 승인을 거쳐 확정된 것으로, 임직원 대상 주식 보상 목적으로 발행됩니다.…more
$2.37+1.94%vs prev closeView filingShare - 8.11Pre-market26.08.11 21:1010-QEarnings
Protara Therapeutics, Inc.
프로타라 테라퓨틱스(TARA)는 2026년 2분기 실적 보고를 통해 2,167만 달러의 순손실을 기록했으며, 이는 전년 동기 1,497만 달러 대비 손실이 확대된 수치입니다. 회사는 2024년 주식 인센티브 플랜의 주식 발행 한도를 930만 주로 상향하는 수정안을 승인했으며, 정관 개정을 통해 발행 가능한 총 주식 수를 2억 1,000만 주로 변경했습니다.…more
$2.37+1.94%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:01#●●●#●●●
Protara Therapeutics Completes Enrollment for Phase 2b Trial of IV Choline Chloride…more
Protara Therapeutics has finished enrolling 24 patients for its Phase 2b clinical trial of IV Choline Chloride for intestinal failure. Interim data is expected in the fourth quarter, though the clinical progress remains at an early stage without proven efficacy.…more
$2.37+1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.8After-hours26.09.09 05:05
●●●●●●●● ●●●●● ●●●●●●
Protara Therapeutics announced that its management will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. This event participation is a standard corporate update and does not provide immediate material impact on the stock.…more
$2.37+1.94%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report